Immunophenotype of original patient biopsy sample compared with spleen-derived cells following primary, secondary, and tertiary engraftment
Xenograft . | Origin of sample . | Immunophenotype (%) . |
|---|---|---|
| ALL-2 | Biopsy | HLA-DR+/CD19+/3-/10+/34- (2) |
| NOD/SCID 1° | HLA-DR+/CD19+/3-/10+/34+ (86) | |
| NOD/SCID 2° | HLA-DR+/CD19+/3-/10+/34+ (89) | |
| NOD/SCID 3° | HLA-DR+/CD19+/3-/10+/34+ (92) | |
| ALL-3 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10- |
| ALL-4 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/22+/10+/34+ |
| ALL-7 | Biopsy | HLA-DR+/CD19+/3-/10+/34-/11b+/ 33+/13+ (52) |
| NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10+/34-/11b+/ 33+/13- (< 1) | |
| ALL-8 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR-/CD19-/3+/2+/7+/8+/ 34-/13+ |
| ALL-10 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10+/34+ |
| ALL-11 | Biopsy | HLA-DR+/CD19+/3-/10+/33-/34- (< 1) |
| NOD/SCID 1° | HLA-DR+/CD19+/3-/10+/33-/34+ (40) | |
| NOD/SCID 2° | HLA-DR+/CD19+/3-/10+/33-/34+ (40) | |
| NOD/SCID 3° | HLA-DR+/CD19+/3-/10+/33-/34+ (33) | |
| ALL-16 | Biopsy | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10- (26) |
| NOD/SCID 1° | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10+ (42) | |
| NOD/SCID 2° | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10+ (30) | |
| NOD/SCID 3° | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10- (< 1) | |
| ALL-17 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10+/34+/33- |
| ALL-19 | Biopsy | HLA-DR+/CD19+/3-/22+/10+/34+/ 33- (< 1) |
| NOD/SCID 1° | HLA-DR+/CD19+/3-/22+/10+/34+/ 33- (< 1) | |
| NOD/SCID 2° | HLA-DR+/CD19+/3-/22+/10+/34+/ 33+ (49) | |
| NOD/SCID 3° | HLA-DR+/CD19+/3-/22+/10+/34+/ 33- (< 1) |
Xenograft . | Origin of sample . | Immunophenotype (%) . |
|---|---|---|
| ALL-2 | Biopsy | HLA-DR+/CD19+/3-/10+/34- (2) |
| NOD/SCID 1° | HLA-DR+/CD19+/3-/10+/34+ (86) | |
| NOD/SCID 2° | HLA-DR+/CD19+/3-/10+/34+ (89) | |
| NOD/SCID 3° | HLA-DR+/CD19+/3-/10+/34+ (92) | |
| ALL-3 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10- |
| ALL-4 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/22+/10+/34+ |
| ALL-7 | Biopsy | HLA-DR+/CD19+/3-/10+/34-/11b+/ 33+/13+ (52) |
| NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10+/34-/11b+/ 33+/13- (< 1) | |
| ALL-8 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR-/CD19-/3+/2+/7+/8+/ 34-/13+ |
| ALL-10 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10+/34+ |
| ALL-11 | Biopsy | HLA-DR+/CD19+/3-/10+/33-/34- (< 1) |
| NOD/SCID 1° | HLA-DR+/CD19+/3-/10+/33-/34+ (40) | |
| NOD/SCID 2° | HLA-DR+/CD19+/3-/10+/33-/34+ (40) | |
| NOD/SCID 3° | HLA-DR+/CD19+/3-/10+/33-/34+ (33) | |
| ALL-16 | Biopsy | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10- (26) |
| NOD/SCID 1° | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10+ (42) | |
| NOD/SCID 2° | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10+ (30) | |
| NOD/SCID 3° | HLA-DR-/CD19-/3-/7+/8+/33-/ 13-/10- (< 1) | |
| ALL-17 | Biopsy; NOD/SCID 1°, 2°, 3° | HLA-DR+/CD19+/3-/10+/34+/33- |
| ALL-19 | Biopsy | HLA-DR+/CD19+/3-/22+/10+/34+/ 33- (< 1) |
| NOD/SCID 1° | HLA-DR+/CD19+/3-/22+/10+/34+/ 33- (< 1) | |
| NOD/SCID 2° | HLA-DR+/CD19+/3-/22+/10+/34+/ 33+ (49) | |
| NOD/SCID 3° | HLA-DR+/CD19+/3-/22+/10+/34+/ 33- (< 1) |
Boldface denotes differences in expression between biopsy and NOD/SCID engrafted cells, with the proportion of positive cells in parentheses. The cut-off for positivity was set at 30% of cells staining more intensely than the isotype control antibody, consistent with standard hematologic procedures (see “Materials and methods” for details). In the interest of space, complete data are shown only for those xenografts that exhibited any differences in immunophenotype following engraftment.
1° indicates primary engraftment; 2°, secondary engraftment; 3°, tertiary engraftment.